U.S. Renewable Energy Stock News

If you are wondering whether MannKind at around US$3.40 is a bargain or a value trap, the key question is how its current price compares with what the business might be worth. The stock has had a weak run recently, with the share price down about 9.8% over the last week, 3.4% over the past month, and 39.3% year to date, contributing to a 22.4% decline over the last year and a 16.0% fall over five years. Recent coverage has focused on MannKind's position within the broader Biotechs industry...

In early June 2026, Artisan Partners Asset Management reported preliminary assets under management of US$186.0 billion as of May 31, while broader sector rotation and concerns around redemption limits at peers stirred sentiment across alternative asset managers. This combination of firm-specific asset data and industry-wide liquidity worries has sharpened investor focus on how Artisan Partners’ business mix and expansion plans interact with market conditions. Next, we will examine how the...

Why Sanmina stock is drawing fresh attention Sanmina (SANM) is back on investor radar after a sharp single day move, with the stock falling 0.1% in the latest session but still reflecting strong longer term total returns. That combination, a modest daily decline alongside sizeable gains over the past month, past 3 months, year to date and past year, invites a closer look at what kind of company is sitting behind the recent share price action. See our latest analysis for Sanmina. Sanmina’s...

Moog stock snapshot after recent performance Moog (MOG.A) has drawn investor attention after a strong run over the past year, with the stock up about 99% on a total return basis and recent gains over the past month and past 3 months. See our latest analysis for Moog. With the share price at about $368.25, Moog has seen a 17.3% 1 month share price return and a 47.4% year to date share price return, while the 1 year total shareholder return of 99.2% and 5 year total shareholder return of 330.4%...

Mattel (NasdaqGS:MAT) is extending the Barbie movie momentum with a planned Masters of the Universe film. The company is launching a Barbie themed campaign with Dunkin' that brings the brand into food and beverage. Mattel is rolling out Mattel Brick Shop building sets, entering direct competition with established building brands and new product segments. For investors watching NasdaqGS:MAT, this cluster of moves sits at the intersection of toys, entertainment, and consumer partnerships...

If you are wondering whether Estée Lauder Companies stock is starting to look interesting on price alone, the recent mix of long term losses and shorter term gains makes it a timely moment to reassess what you are really paying for. The stock last closed at US$83.49, with the share price down 6.1% over the past week and down 3.1% over the past month, even though the 1 year return sits at 23.7% after large declines of 50.0% over 3 years and 70.0% over 5 years. These moves come as investors...

Galaxy Digital (NasdaqGS:GLXY) appears on the Fortune 500 list for the first time, marking a new level of scale and recognition for the crypto focused financial services company. Morgan Stanley Wealth Management and Galaxy Digital announce a partnership to support institutional crypto lending and access to regulated exchange traded products. The tie up is aimed at making it easier for institutional clients to move between direct crypto exposure and listed vehicles within existing wealth...

Travere Therapeutics (TVTX) is back in focus after new long term data from its Phase 3 DUPLEX Study open label extension showed sustained, clinically meaningful proteinuria reductions in focal segmental glomerulosclerosis patients on FILSPARI. See our latest analysis for Travere Therapeutics. The latest DUPLEX data and recent licensing moves have arrived after a powerful run, with Travere’s share price up 58.07% over 90 days and a 1 year total shareholder return close to 3x, although short...

Exelixis recently reported subgroup results from the phase 3 CABINET trial showing that CABOMETYX significantly improved progression-free survival versus placebo in previously treated patients with advanced neuroendocrine tumors, regardless of functional status. Because CABOMETYX already has U.S. approval for pancreatic and extra-pancreatic neuroendocrine tumors, these ASCO 2026 data mainly strengthen the drug’s clinical profile and potential real-world uptake rather than opening an entirely...

Venture Global (NYSE:VG) has issued $2.25b in senior secured notes to refinance higher interest debt. The refinancing extends debt maturities and reduces borrowing costs, targeting a stronger long term balance sheet. The transaction is positioned to support the company’s future expansion plans and capital needs. For investors watching Venture Global at a share price of $12.8, this $2.25b refinancing sits alongside a mixed recent track record. The stock is up 6.3% over the past week and...

Why Cactus stock is drawing fresh attention Cactus (WHD) is back on investor radars after recent trading left the stock at a last close of $56.62, with returns mixed across the past week, month, and past 3 months. See our latest analysis for Cactus. While the share price slipped around 4% in the last session and is slightly down over the week, the 30 day share price return of 4.6% and year to date share price gain of 20.4% suggest momentum has generally been building. This is supported by a 1...

SM Energy Company recently declared a quarterly cash dividend of US$0.22 per share, payable on June 22, 2026 to shareholders of record as of June 8, 2026, while also redeeming all remaining 6.75% senior notes due 2026 and closing a US$900 million South Texas asset sale to cut debt. These actions, alongside record 2025 operating cash flow, higher 2026 production guidance, Civitas merger synergies, a 10% dividend increase and planned share repurchases, point to a company prioritizing balance...

Wondering if Berkshire Hathaway stock at around US$488 a share still offers value or if most of the upside is already priced in? This article walks through what the numbers are saying about valuation. The stock has moved 2.9% over the past week and 2.6% over the past month, while the year to date return is down 1.8% and the 1 year return is down 1.1%. This helps frame how the market has recently been reassessing both opportunity and risk. Recent coverage has focused on Berkshire Hathaway's...

GitLab (GTLB) has become a focus for investors after reporting quarterly revenue and earnings above expectations, lifting full year guidance while simultaneously announcing a large restructuring centered on AI priorities and cost savings. See our latest analysis for GitLab. Recent news around Q1 beats, higher guidance and the AI focused restructuring has come alongside a 19.8% 1 month share price return and 26.6% 3 month share price return. However, the 1 year total shareholder return is...

If you are wondering whether Corebridge Financial at around US$26.86 is priced for opportunity or already reflects expectations, the next sections will focus squarely on what the current market price might be implying. The stock has been weak in the short term, with the share price down 0.5% over the last week, down 1.6% over the past month, and down 11.6% year to date, although the three year return stands at 98.5% and the one year return is down 16.6%. Recent coverage has focused on...

If you are wondering whether Eli Lilly stock still offers value at current levels, the answer depends heavily on which valuation lens you use and how you weigh future expectations against today's price. The stock recently closed at US$1,131.42, with returns of 2.4% over the past week, 19.3% over the past month, 4.7% year to date, 48.0% over the last year and 159.1% over the past three years. Recent headlines have continued to focus on Eli Lilly's role in large pharmaceutical markets and the...

In June 2026, Alignment Healthcare (NasdaqGS:ALHC) was named to the Fortune 1000 list for the second year in a row. The company advanced more than 196 positions and is the only business solely focused on Medicare Advantage in the Healthcare: Insurance and Managed Care category. Founder and CEO John Kao is taking on the additional role of Chairman of the Board, alongside new executive appointments aimed at supporting future scale. For investors tracking Alignment Healthcare at a share price...

In early June 2026, reports emerged that Visa, Mastercard, Stripe, and potentially Coinbase were developing a new stablecoin platform that could compete with Circle Internet Group’s USDC, while Circle also expanded distribution through partners such as Hyperliquid and Nium and saw several pre-planned insider share sales and tax-related share withholdings. An interesting twist is that as regulatory changes have pushed euro stablecoins to consolidate, Circle’s EURC has grown to around half of...

Itron (NasdaqGS:ITRI) announced expanded smart water partnerships with Hunter Water in Australia and the Office d'Equipement Hydraulique de Corse in France. The projects involve broad deployments of advanced water metering and cloud-based management platforms across the two utilities. These initiatives target water conservation, operational efficiency, and reduced non revenue water loss in key international markets. Itron focuses on grid edge solutions for utilities, including smart...

Uniti Group Inc. previously filed a US$184.92 million shelf registration for 16,750,000 common shares tied to an ESOP-related offering, and more recently its Kinetic ABS Issuer LLC subsidiary priced about US$1.14 billion in secured fiber network revenue term notes backed by residential fiber assets and customer contracts across multiple states. Together with Kinetic surpassing 2 million fiber premises built, these financing and build-out milestones highlight Uniti’s push to deepen fiber...

Everpure (P) opened 2027 with Q1 revenue of US$1.1 billion and basic EPS of US$0.07, alongside trailing twelve month revenue of US$3.9 billion and EPS of US$0.69 that frame the latest quarter in a broader context. Over the past year, the company has seen revenue move from US$3.3 billion to US$3.9 billion and EPS build from US$0.39 to US$0.69, setting the scene for investors to focus on how margins are holding up through this reporting stretch. See our full analysis for Everpure. With the...

In late May and early June 2026, Corcept Therapeutics reported strong overall survival data for newly approved ovarian cancer drug Lifyorli from its Phase 3 ROSELLA trial at ASCO, while also disclosing that the U.S. Department of Justice declined to intervene in a long-running qui tam lawsuit related to Korlym’s promotion and reimbursement. Beyond reinforcing Lifyorli’s clinical profile and guideline inclusion, these updates highlight Corcept’s evolution from a single-product Cushing’s...

Builders FirstSource Board member Mark A. Alexander resigned from the Board of Directors, effective June 3, 2026. The company stated the decision was due to health reasons and not related to any disagreement over strategy or operations. The change affects the corporate governance structure at Builders FirstSource, which may be relevant for current and prospective shareholders. For investors watching Builders FirstSource (NYSE:BLDR), this Board change comes as the stock trades at $73.64. The...

In early June 2026, Motorola Solutions introduced SafetyCam, a wearable AI assistant that combines video security, two-way communications, a panic button and conversational Assist AI to support retail and other front-line teams with real-time incident visibility and response. By moving beyond passive recording to proactive threat detection, live remote intervention and multilingual voice assistance, SafetyCam deepens Motorola Solutions’ push into integrated, software-rich safety ecosystems...